Guo J, Wu J, He Q, Zhang M, Li H, Liu Y
Cells. 2022; 11(21).
PMID: 36359869
PMC: 9653757.
DOI: 10.3390/cells11213474.
Sanjay , Sharma A, Lee H
Biomedicines. 2021; 9(12).
PMID: 34944727
PMC: 8698906.
DOI: 10.3390/biomedicines9121914.
Afzal H, Khan N, Sultana K, Mobashar A, Lareb A, Khan A
ACS Omega. 2021; 6(6):4470-4479.
PMID: 33623853
PMC: 7893790.
DOI: 10.1021/acsomega.0c06064.
Kirsten T, Casarin R, Bernardi M, Felicio L
Biol Open. 2019; 8(5).
PMID: 31036753
PMC: 6550086.
DOI: 10.1242/bio.041327.
Caberlotto L, Nguyen T, Lauria M, Priami C, Rimondini R, Maioli S
Sci Rep. 2019; 9(1):3965.
PMID: 30850634
PMC: 6408545.
DOI: 10.1038/s41598-019-39828-5.
Jujuboside A promotes Aβ clearance and ameliorates cognitive deficiency in Alzheimer's disease through activating Axl/HSP90/PPARγ pathway.
Zhang M, Qian C, Zheng Z, Qian F, Wang Y, Thu P
Theranostics. 2018; 8(15):4262-4278.
PMID: 30128052
PMC: 6096387.
DOI: 10.7150/thno.26164.
Pioglitazone abolishes autistic-like behaviors via the IL-6 pathway.
Kirsten T, Casarin R, Bernardi M, Felicio L
PLoS One. 2018; 13(5):e0197060.
PMID: 29791472
PMC: 5965820.
DOI: 10.1371/journal.pone.0197060.
Insulin degrading enzyme contributes to the pathology in a mixed model of Type 2 diabetes and Alzheimer's disease: possible mechanisms of IDE in T2D and AD.
Li H, Wu J, Zhu L, Sha L, Yang S, Wei J
Biosci Rep. 2017; 38(1).
PMID: 29222348
PMC: 6435468.
DOI: 10.1042/BSR20170862.
Role of insulin resistance in Alzheimer's disease.
Cai Z, Xiao M, Chang L, Yan L
Metab Brain Dis. 2014; 30(4):839-51.
PMID: 25399337
DOI: 10.1007/s11011-014-9631-3.
Roles of AMP-activated protein kinase in Alzheimer's disease.
Cai Z, Yan L, Li K, Quazi S, Zhao B
Neuromolecular Med. 2012; 14(1):1-14.
PMID: 22367557
DOI: 10.1007/s12017-012-8173-2.
Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease.
de la Monte S
Curr Alzheimer Res. 2012; 9(1):35-66.
PMID: 22329651
PMC: 3349985.
DOI: 10.2174/156720512799015037.
Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease.
de la Monte S
Front Biosci (Elite Ed). 2011; 4(4):1582-605.
PMID: 22201977
PMC: 4550311.
DOI: 10.2741/e482.
Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease.
de la Monte S
Drugs. 2011; 72(1):49-66.
PMID: 22191795
PMC: 4550303.
DOI: 10.2165/11597760-000000000-00000.
Insulin is differentially related to cognitive decline and atrophy in Alzheimer's disease and aging.
Burns J, Honea R, Vidoni E, Hutfles L, Brooks W, Swerdlow R
Biochim Biophys Acta. 2011; 1822(3):333-9.
PMID: 21745566
PMC: 3264795.
DOI: 10.1016/j.bbadis.2011.06.011.
Growth hormone/insulin-like growth factor I axis in neurodegenerative diseases.
Gasperi M, Castellano A
J Endocrinol Invest. 2010; 33(8):587-91.
PMID: 20930497
DOI: 10.1007/BF03346653.
The interrelationship between mitochondrial dysfunction and transcriptional dysregulation in Huntington disease.
Jin Y, Johnson G
J Bioenerg Biomembr. 2010; 42(3):199-205.
PMID: 20556492
PMC: 2913874.
DOI: 10.1007/s10863-010-9286-7.
Alzheimer's disease is type 3 diabetes-evidence reviewed.
de la Monte S, Wands J
J Diabetes Sci Technol. 2009; 2(6):1101-13.
PMID: 19885299
PMC: 2769828.
DOI: 10.1177/193229680800200619.
PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia.
Qin W, Haroutunian V, Katsel P, Cardozo C, Ho L, Buxbaum J
Arch Neurol. 2009; 66(3):352-61.
PMID: 19273754
PMC: 3052997.
DOI: 10.1001/archneurol.2008.588.
Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease.
Quintanilla R, Jin Y, Fuenzalida K, Bronfman M, Johnson G
J Biol Chem. 2008; 283(37):25628-25637.
PMID: 18640979
PMC: 2533094.
DOI: 10.1074/jbc.M804291200.
Cognitive dysfunction and diabetes mellitus.
Kodl C, Seaquist E
Endocr Rev. 2008; 29(4):494-511.
PMID: 18436709
PMC: 2528851.
DOI: 10.1210/er.2007-0034.
